{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:42:29Z","timestamp":1784720549571,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171339"],"award-info":[{"award-number":["82171339"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82571536"],"award-info":[{"award-number":["82571536"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.clim.2026.110682","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T20:21:04Z","timestamp":1771359664000},"page":"110682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Polymorphonuclear myeloid-derived suppressor cells inhibit natural killer cell function in neuromyelitis optica spectrum disorder via the CD155-TIGIT axis"],"prefix":"10.1016","volume":"284","author":[{"given":"Chao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghao","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daidi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clim.2026.110682_bb0005","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1474-4422(12)70133-3","article-title":"Aquaporin 4 and neuromyelitis optica","volume":"11","author":"Papadopoulos","year":"2012","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.clim.2026.110682_bb0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"issue":"9451","key":"10.1016\/j.clim.2026.110682_bb0015","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.clim.2026.110682_bb0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3390\/ijms17030273","article-title":"The immunology of neuromyelitis optica-current knowledge, clinical implications, controversies and future perspectives","volume":"17","author":"Jasiak-Zatonska","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.clim.2026.110682_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-022-02661-1","article-title":"Upregulated complement receptors correlate with fc gamma receptor 3A-positive natural killer and natural killer-T cells in neuromyelitis optica spectrum disorder","volume":"19","author":"Nishiyama","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"5","key":"10.1016\/j.clim.2026.110682_bb0030","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000852","article-title":"High-throughput investigation of molecular and cellular biomarkers in NMOSD","volume":"7","author":"Yandamuri","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.clim.2026.110682_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jocn.2019.11.022","article-title":"The differential expression of natural killer cells in NMOSD and MS","volume":"71","author":"Ding","year":"2020","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.clim.2026.110682_bb0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.coi.2018.03.009","article-title":"Plasticity of myeloid-derived suppressor cells in cancer","volume":"51","author":"Tcyganov","year":"2018","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110682_bb0045","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.clim.2026.110682_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01099","article-title":"Myeloid-derived suppressor cells: not only in tumor immunity","volume":"10","author":"Pawelec","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110682_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.clim.2026.110682_bb0060","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.4049\/jimmunol.181.8.5791","article-title":"Subsets of myeloid-derived suppressor cells in tumor-bearing mice","volume":"181","author":"Youn","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110682_bb0065","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2026.110682_bb0070","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3389\/fimmu.2018.00527","article-title":"Contribution to tumor angiogenesis from innate immune cells within the tumor microenvironment: implications for immunotherapy","volume":"9","author":"Albini","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.clim.2026.110682_bb0075","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110682_bb0080","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12943-023-01800-3","article-title":"Co-inhibition of TIGIT and PD-1\/PD-L1 in Cancer immunotherapy: mechanisms and clinical trials","volume":"22","author":"Chu","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.clim.2026.110682_bb0085","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00771","article-title":"Myeloid derived suppressor cells interactions with natural killer cells and pro-angiogenic activities: roles in tumor progression","volume":"10","author":"Bruno","year":"2019","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2026.110682_bb0090","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.clim.2026.110682_bb0095","article-title":"Rituximab at lower dose for neuromyelitis optica spectrum disorder: a multicenter, open-label, self-controlled, prospective follow-up study","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.clim.2026.110682_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e31533","article-title":"The ratio of circulating CD56dim NK cells to follicular T helper cells as a promising predictor for disease activity of relapsing-remitting multiple sclerosis","volume":"10","author":"Ding","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.clim.2026.110682_bb0105","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.imlet.2019.10.006","article-title":"CD3(\u2212)CD56(+) NK cells display an inflammatory profile in RR-MS patients","volume":"216","author":"Tahrali","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.clim.2026.110682_bb0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fimmu.2013.00063","article-title":"The role of natural killer cells in multiple sclerosis and their therapeutic implications","volume":"4","author":"Chanvillard","year":"2013","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2026.110682_bb0115","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.4049\/jimmunol.1000569","article-title":"Involvement of CD226+ NK cells in immunopathogenesis of systemic lupus erythematosus","volume":"186","author":"Huang","year":"2011","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2026.110682_bb0120","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-012-0986-4","article-title":"Neuromyelitis optica IgG and natural killer cells produce NMO lesions in mice without myelin loss","volume":"123","author":"Ratelade","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"1","key":"10.1016\/j.clim.2026.110682_bb0125","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200173","article-title":"Long-term effects of IL-6 receptor blockade therapy on regulatory lymphocytes and neutrophils in neuromyelitis Optica Spectrum disorder","volume":"11","author":"Matsuoka","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.clim.2026.110682_bb0130","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.clim.2026.110682_bb0135","article-title":"The levels of circulating cytokines and risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study","volume":"15","author":"Ma","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2026.110682_bb0140","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.clim.2026.110682_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-derived suppressor cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"2","key":"10.1016\/j.clim.2026.110682_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001223","article-title":"Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation","volume":"8","author":"Cassetta","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.clim.2026.110682_bb0155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ccell.2023.02.009","article-title":"Functional states of myeloid cells in cancer","volume":"41","author":"van Vlerken-Ysla","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.clim.2026.110682_bb0160","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.4049\/jimmunol.1101816","article-title":"Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease","volume":"188","author":"Ioannou","year":"2012","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2026.110682_bb0165","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.4049\/jimmunol.1200086","article-title":"Mouse CD11b+gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis","volume":"189","author":"Yi","year":"2012","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2026.110682_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1021612","article-title":"Myeloid-derived suppressor cell: a crucial player in autoimmune diseases","volume":"13","author":"Xu","year":"2022","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2026.110682_bb0175","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nri3799","article-title":"Balancing natural killer cell activation through paired receptors","volume":"15","author":"Martinet","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.clim.2026.110682_bb0180","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2407-4-73","article-title":"CD155\/PVR plays a key role in cell motility during tumor cell invasion and migration","volume":"4","author":"Sloan","year":"2004","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clim.2026.110682_bb0185","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3389\/fimmu.2013.00508","article-title":"The DNA damage response: a common pathway in the regulation of NKG2D and DNAM-1 ligand expression in normal, infected, and cancer cells","volume":"4","author":"Cerboni","year":"2014","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.clim.2026.110682_bb0190","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/0008-5472.CAN-16-0839","article-title":"Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells","volume":"76","author":"Sarhan","year":"2016","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.clim.2026.110682_bb0195","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.clim.2026.110682_bb0200","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12974-022-02600-0","article-title":"Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD","volume":"19","author":"Schroeder-Castagno","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"12","key":"10.1016\/j.clim.2026.110682_bb0205","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/ni1276","article-title":"Resolution of inflammation: the beginning programs the end","volume":"6","author":"Serhan","year":"2005","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2026.110682_bb0210","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.clim.2026.110682_bb0215","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and Cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"issue":"747","key":"10.1016\/j.clim.2026.110682_bb0220","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adi2952","article-title":"Tumor-associated NK cells drive MDSC-mediated tumor immune tolerance through the IL-6\/STAT3 axis","volume":"16","author":"Neo","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.clim.2026.110682_bb0225","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaf8943","article-title":"Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients","volume":"1","author":"Condamine","year":"2016","journal-title":"Sci. Immunol."},{"issue":"12","key":"10.1016\/j.clim.2026.110682_bb0230","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41590-018-0237-5","article-title":"Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity","volume":"19","author":"Knier","year":"2018","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2026.110682_bb0235","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat. Immunol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:44:15Z","timestamp":1777617855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"alternative-id":["S1521661626000203"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110682","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Polymorphonuclear myeloid-derived suppressor cells inhibit natural killer cell function in neuromyelitis optica spectrum disorder via the CD155-TIGIT axis","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110682"}}